GlassScriptPhysician profile
Vasko K Gulevski
NPI 1528011517
$23,681.66
in general payments reported to CMS, 2019-2025
69 companies · $3,388 in 2025
The $3,388 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $1,544 · 2021: $2,683 · 2022: $2,762 · 2023: $8,075 · 2024: $3,254 · 2025: $3,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,829 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,828.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,887.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,767.87 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,536.87 | 2019-2025 | |
| Pfizer INC. | $1,483.83 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,480.49 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Emd Serono, INC. | $1,441.70 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $1,093.44 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $1,021.58 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Supernus Pharmaceuticals, INC. | $505.48 | 2019-2024 | Qelbree |
| Allergan, INC. | $485.02 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $466.02 | 2022 | |
| Alexion Pharmaceuticals, INC. | $375.11 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $368.25 | 2021-2025 | Rexulti, Vyepti |
| Neurelis, INC. | $355.39 | 2021-2025 | Valtoco |
| Sunovion Pharmaceuticals INC. | $334.58 | 2019-2022 | |
| Grifols USA, LLC | $287.28 | 2019-2025 | Gamunex-C, Xembify |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasko Gulevski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.